The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy
- PMID: 40721807
- PMCID: PMC12304164
- DOI: 10.1038/s41598-025-12400-0
The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy
Abstract
Post hepatectomy liver failure (PHLF) poses a significant threat to the prognosis of patients with hepatocellular carcinoma (HCC), particularly those undergoing major hepatectomy. The present research endeavors to clarify the influence of prealbumin on the development of PHLF in HCC patients who have undergone major hepatectomy. Patients with HCC who have undergone major hepatectomy were included. Based on the ROC curve, the optimal cut-off value for prealbumin was determined and patients were divided into two groups. Univariate and multivariate logistic analyses were conducted to identify risk factors for PHLF in HCC patients. Furthermore, the predictive ability of PHLF was also evaluated. 466 patients were included, among whom 98 (21%) developed PHLF. Compared with the high prealbumin group, patients in the low prealbumin group had significantly higher proportions of cirrhosis, portal hypertension, intraoperative blood loss, and transfusion, as well as a higher incidence of PHLF (12.3% vs. 23.5%, P = 0.011). Multivariate analysis revealed that prealbumin is a risk factor for PHLF (HR 1.446, 95%CI 1.091-2.369, P = 0.015), but it is not a risk factor for severe PHLF (HR 1.183, 95%CI 0.584-2.692, P = 0.289). However, the comprehensive indicator, prealbumin-bilirubin (preALBI), is not only a risk factor for PHLF but also severe PHLF. Furthermore, its predictive performance is significantly higher than that of other related indicators (all P < 0.05). Patients with low prealbumin levels require perioperative protocols: precise resection control, liver volume assessment, and PHLF prevention monitoring.
Keywords: Hepatocellular carcinoma; Major hepatectomy; Post hepatectomy liver failure; Prealbumin; Prealbumin-bilirubin.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures

Similar articles
-
Pre-operative evaluation of spontaneous portosystemic shunts as a predictor of post-hepatectomy liver failure in patients undergoing liver resection for hepatocellular carcinoma.Eur J Surg Oncol. 2025 Aug;51(8):108778. doi: 10.1016/j.ejso.2024.108778. Epub 2024 Oct 22. Eur J Surg Oncol. 2025. PMID: 39490238
-
Comparing the accuracy of prediction models to detect clinically relevant post-hepatectomy liver failure early after major hepatectomy.Br J Surg. 2024 Jan 3;111(1):znad433. doi: 10.1093/bjs/znad433. Br J Surg. 2024. PMID: 38150185 Free PMC article.
-
CT-based detection of clinically significant portal hypertension predicts post-hepatectomy outcomes in hepatocellular carcinoma.Eur Radiol. 2025 Aug;35(8):4980-4992. doi: 10.1007/s00330-025-11411-9. Epub 2025 Feb 14. Eur Radiol. 2025. PMID: 39953152
-
A systematic review of prediction models for post-hepatectomy liver failure in patients undergoing liver surgery.HPB (Oxford). 2021 Sep;23(9):1311-1320. doi: 10.1016/j.hpb.2021.05.002. Epub 2021 May 19. HPB (Oxford). 2021. PMID: 34090805
-
Predictive value of gadoxetic acid-enhanced MRI for posthepatectomy liver failure: a systematic review.Eur Radiol. 2022 Mar;32(3):1792-1803. doi: 10.1007/s00330-021-08297-8. Epub 2021 Sep 25. Eur Radiol. 2022. PMID: 34562137 Free PMC article.
References
-
- Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet400 (10360), 1345–1362 (2022). - PubMed
-
- Liang, L. et al. Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis. HPB Off. J. Int. Hepato Pancreato Biliary Assoc. 20 (2), 110–119 (2018). - PubMed
-
- Couinaud, C. Liver anatomy: Portal (and suprahepatic) or biliary segmentation. Dig. Surg.16 (6), 459–467 (1999). - PubMed
MeSH terms
Substances
Grants and funding
- No. 82203403/National Natural Science Foundation of China
- No. 82302915/National Natural Science Foundation of China
- No. LGF22H030012/fund of Public Welfare Technology Research Program of Zhejiang Provincial Natural Science Foundation
- No. Y202146104/General Research Program of Zhejiang Provincial Department of Education
- No. KYQN202113/the Basic Research Funds for Hangzhou Medical College Basic Research Program
LinkOut - more resources
Full Text Sources
Medical
Research Materials